TARSONS PRODUCTS LIMITED Fair Value
TARSONS · Healthcare · Current price ₹345
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹78 | 2% ROE fading to 13% over ~10 yrs, on ₹119 book |
| Relative P/E | ₹182 | EPS × 67.8 peer-median P/E |
| Graham floor | ₹85 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is TARSONS PRODUCTS LIMITED undervalued?
DocStoX estimates the fair value of TARSONS PRODUCTS LIMITED at ₹108 per share, versus the current market price of ₹345. That puts the stock about -68.6% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹78), Relative P/E (₹182), Graham floor (₹85). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹78 (bear) to ₹108 (base) to ₹182 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on TARSONS PRODUCTS LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.